Fast Track Immunotherapeutic Development with MuScreen™

oncology-magnifyglass.png

"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

MuScreen, CrownBio's High Throughput Syngeneic In Vivo Screen for Evaluating Immunotherapies

Limited Volume - Winter Enrollment Ends 28 February 2018

 
  • Built upon our collection of validated and well-characterized syngeneic models, and leveraging detailed model checkpoint inhibitor benchmarking data, as well as RNAseq and optional FACS analysis information

  • Comprising of a predesignated syngeneic panel across a range of cancer types

  • Evaluate TGI with the Syngeneic Efficacy Screening Panel of 12 models

  • Models run on a large scale, preset schedule, with shared vehicle and common groups to improve efficiency, reproducibility, and cost-effectiveness
muscreen-flow.png

Choose MuScreen Over a Traditional In Vitro Study

  • An effective and accurate way to find the right model - particularly for combination studies

  • Large-scale, staggered screening to reduce variability from sources such as antibodies and mice

  • Improve efficiency and save study time by rapidly identifying markers or models 

  • Benefit from multiple clients sharing the results of vehicle and other common groups significantly reducing both the number of animals needed and associate costs

Request MuScreen Pricing